Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 10/20 | 1.00 |
| ▸ | CES1 | P23141 | 10/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.56 |
| ▸ | BAD | Q92934 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340223 | 0.92 | CES2 (0.84) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL1480034 | 0.89 | CES2 (0.80) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL28143683 | 0.88 | CES2 (0.79) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL3830978 | 0.87 | CES2 (0.76) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL8065627 | 0.87 | CES2 (0.76) | CES2CES1CA1CA2 | |
| SCHEMBL3830974 | 0.87 | CES2 (0.76) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL15679982 | 0.87 | CES2 (0.76) | CES2CES1CA1CA2NPC1 | |
| SCHEMBL263831 | 0.86 | CES2 (0.75) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL4214960 | 0.86 | CES2 (0.75) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL15180835 | 0.86 | CES2 (0.75) | CES2CES1CA1CA2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894870-B | Polymer and polymer nanoparticle of benzobisquinoxaline receptor for photothermal therapy, and preparation and application thereof | 华南理工大学 | 2024-06-25 | — | — | CN | claimed |
| CN-115894870-A | Polymer and polymer nanoparticle of benzo-bis-quinoxaline receptor for photothermal therapy, and preparation and application thereof | 华南理工大学 | 2023-04-04 | — | — | CN | claimed |
| CN-113387934-B | Polyaryl substituted imidazole derivative and preparation method and application thereof | 中山大学 | 2023-03-07 | — | — | CN | claimed |
| CN-113387934-A | Polyaryl substituted imidazole derivative and preparation method and application thereof | 中山大学 | 2021-09-14 | — | — | CN | claimed |
| CN-105925258-B | A kind of fluorescent organic molecule H2hpi2cf and its preparation method and application based on ESIPT characteristic | 中山大学 | 2019-01-29 | — | — | CN | claimed |
| CN-105925258-A | Fluorescent organic molecule H2hpi2cf based on ESIPT characteristic and preparation method and application thereof | 中山大学 | 2016-09-07 | — | — | CN | claimed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | claimed |
| US-6156812-A | Nanoporous material fabricated using polymeric template strands | HONEYWELL INTERNATIONAL INC. (US) | 2000-12-05 | — | — | US | claimed |
| US-5463135-A | Fluorinated benzils and a process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-31 | — | — | US | claimed |
| EP-0596395-A1 | Fluorinated benzils and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | EP | claimed |
| CN-121379351-B | Nano ceramic ultra-high hardness powder coating and preparation method thereof | 广东桑瑞斯环保新材料有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| CN-120137168-A | High-refractive-index hyperbranched polyolefin thioether compound, preparation method thereof and post-functionalization method | 华南理工大学 | 2025-06-13 | — | — | CN | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-118619893-A | PGI2 receptor agonist compounds, pharmaceutical compositions and uses | 石家庄四药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-4466976-A | Antiinflammatory and antiallergic imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-08-21 | — | — | US | disclosed |
| EP-0077024-A2 | Imidazole derivatives, process for their preparation and pharmaceutical products containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-04-20 | — | — | EP | disclosed |
| US-4018923-A | 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4013654-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989831-A | Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines | ELI LILLY AND COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CES2 3887/4885CES1 1672/4885CA1 4843/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CES2 3887/4885CES1 1672/4885CA1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.